Maslinic Acid Enhances Immune Responses in Leukemic Mice Through Macrophage Phagocytosis and Natural Killer Cell Activities
Animals
B-Lymphocytes
/ drug effects
Cytotoxicity, Immunologic
/ drug effects
Disease Models, Animal
Humans
Killer Cells, Natural
/ drug effects
Leukemia
/ drug therapy
Leukocytes, Mononuclear
/ drug effects
Lymphocyte Activation
/ drug effects
Macrophages
/ drug effects
Mice
Phagocytosis
/ drug effects
Spleen
/ drug effects
T-Lymphocytes
/ drug effects
Triterpenes
/ administration & dosage
Maslinic acid
immune responses
leukemia WEHI-3 cells
macrophage
natural killer cells
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
20
08
2018
revised:
26
09
2018
accepted:
02
10
2018
entrez:
28
12
2018
pubmed:
28
12
2018
medline:
6
4
2019
Statut:
ppublish
Résumé
Maslinic acid (MA), a pentacyclic triterpene extracted from wax-like coatings of olives, has been shown to reduce cancer cell number through induction of autophagy and apoptosis in many human cancer cells including human leukemia HL-60 cells. In the present study, we investigated whether or not MA affects immune responses in a leukemia mouse model. WEHI-3 cells were intraperitonealIy (i.p.) injected into normal BALB/c mice to develop leukemia. Mice were then treated by i.p. injection with MA at different doses (0, 8, 16 and 32 mg/kg) for 2 weeks. After treatment, all animals were weighed and blood, liver and spleen tissues were weighed. Blood or spleen both were used for determination of cell markers or phagocytosis, natural killer (NK) cell activities and T- and B-cell proliferation, respectively, by using a flow cytometric assay. MA did not significantly affect body, liver, and spleen weights. However, MA increased markers of T-cells (at 16 mg/kg treatment) and monocytes (at 32 mg/kg treatment), but reduced B-cell markers (at 8 mg/kg treatment); MA did not significantly affect cell marker of macrophages. Furthermore, MA increased phagocytosis by macrophages from peripheral blood mononuclear cells and peritoneal cavity at 32 mg/kg treatment and increased NK cell activity at target cell:splenocyte ratio of 25:1 but did not affect B- and T-cell proliferation. MA increased immune responses by enhancing macrophage phagocytosis and NK cell activities in leukemic mice.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Maslinic acid (MA), a pentacyclic triterpene extracted from wax-like coatings of olives, has been shown to reduce cancer cell number through induction of autophagy and apoptosis in many human cancer cells including human leukemia HL-60 cells. In the present study, we investigated whether or not MA affects immune responses in a leukemia mouse model.
MATERIALS AND METHODS
METHODS
WEHI-3 cells were intraperitonealIy (i.p.) injected into normal BALB/c mice to develop leukemia. Mice were then treated by i.p. injection with MA at different doses (0, 8, 16 and 32 mg/kg) for 2 weeks. After treatment, all animals were weighed and blood, liver and spleen tissues were weighed. Blood or spleen both were used for determination of cell markers or phagocytosis, natural killer (NK) cell activities and T- and B-cell proliferation, respectively, by using a flow cytometric assay.
RESULTS
RESULTS
MA did not significantly affect body, liver, and spleen weights. However, MA increased markers of T-cells (at 16 mg/kg treatment) and monocytes (at 32 mg/kg treatment), but reduced B-cell markers (at 8 mg/kg treatment); MA did not significantly affect cell marker of macrophages. Furthermore, MA increased phagocytosis by macrophages from peripheral blood mononuclear cells and peritoneal cavity at 32 mg/kg treatment and increased NK cell activity at target cell:splenocyte ratio of 25:1 but did not affect B- and T-cell proliferation.
CONCLUSION
CONCLUSIONS
MA increased immune responses by enhancing macrophage phagocytosis and NK cell activities in leukemic mice.
Identifiants
pubmed: 30587604
pii: 33/1/65
doi: 10.21873/invivo.11440
pmc: PMC6364079
doi:
Substances chimiques
Triterpenes
0
maslinic acid
E233J88OHQ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
65-73Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Leuk Lymphoma. 2004 Jul;45(7):1311-8
pubmed: 15359628
Comp Biochem Physiol C Toxicol Pharmacol. 2006 Oct;144(2):130-40
pubmed: 16934535
Chem Biodivers. 2006 Sep;3(9):1023-30
pubmed: 17193335
Phytother Res. 2007 Dec;21(12):1171-6
pubmed: 17661332
Am J Reprod Immunol. 2007 Sep;58(3):280-8
pubmed: 17681044
Comp Biochem Physiol C Toxicol Pharmacol. 2008 Mar;147(2):158-67
pubmed: 17945540
Z Naturforsch C. 2007 Sep-Oct;62(9-10):668-72
pubmed: 18069238
Br J Nutr. 2008 Jul;100(1):36-43
pubmed: 18298868
Nat Prod Res. 2008;22(12):1067-73
pubmed: 18780248
Cancer Lett. 2009 Jan 8;273(1):44-54
pubmed: 18790561
Bioorg Med Chem. 2009 Feb 1;17(3):1139-45
pubmed: 19135380
Blood. 2009 Jul 30;114(5):937-51
pubmed: 19357394
J Pediatr Hematol Oncol. 2009 Jun;31(6):393-7
pubmed: 19648787
J Nat Prod. 2010 May 28;73(5):831-4
pubmed: 20441162
Malar J. 2011 Apr 25;10:103
pubmed: 21518429
Br J Cancer. 2011 Nov 22;105(11):1684-92
pubmed: 22045184
Leuk Res. 2012 May;36(5):634-45
pubmed: 22133641
Br J Nutr. 2013 Jan 28;109(2):210-22
pubmed: 22716951
Exp Hematol Oncol. 2012 Nov 29;1(1):36
pubmed: 23210908
Int J Mol Sci. 2013 Feb 18;14(2):4106-20
pubmed: 23429195
J Proteomics. 2013 May 27;83:15-25
pubmed: 23499989
J Nat Prod. 2013 Apr 26;76(4):737-40
pubmed: 23540838
Immunotherapy. 2014;6(1):95-106
pubmed: 24341888
Mol Cell Biochem. 2014 Jul;392(1-2):281-7
pubmed: 24687305
Clin Invest Med. 2014 Aug 01;37(4):E217-24
pubmed: 25090261
Am J Respir Cell Mol Biol. 2015 Nov;53(5):676-88
pubmed: 25870903
Nat Rev Immunol. 2015 Dec;15(12):731-44
pubmed: 26603899
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):E7239-48
pubmed: 26669445
Blood Cancer J. 2016 Jul 01;6(7):e441
pubmed: 27367478
Essays Biochem. 2016 Oct 31;60(3):275-301
pubmed: 27784777
Medicine (Baltimore). 2016 Dec;95(49):e5541
pubmed: 27930550
Anal Cell Pathol (Amst). 2016;2016:2787623
pubmed: 28050335
Endocr Relat Cancer. 2017 Apr;24(4):R123-R144
pubmed: 28193698
Oncol Lett. 2017 Jun;13(6):4875-4881
pubmed: 28599489
Mol Med Rep. 2017 Sep;16(3):2483-2490
pubmed: 28677783
Front Immunol. 2017 Sep 13;8:1124
pubmed: 28955340
Front Med. 2018 Feb;12(1):34-47
pubmed: 29352371
Drug Discov Today. 2018 Dec;23(12):1936-1949
pubmed: 29870791
Am J Hematol. 2018 Jun;93(6):824-840
pubmed: 29878489
In Vivo. 2018 Jul-Aug;32(4):783-790
pubmed: 29936459
J Pathol. 1994 Aug;173(4):303-7
pubmed: 7525907